Parathyroid Adenoma and Primary Hyperparathyroidism: Diagnosis, Localisation and Minimally Invasive Surgery

Parathyroid glands — the body's smallest endocrine organs; normally 4 (two on the back of each thyroid lobe), 3-6 mm in size, total weight 120-150 mg. They regulate calcium metabolism through parathyroid hormone (PTH) secretion. PTH mobilises calcium from bone, reabsorbs calcium in the kidney, and stimulates active vitamin D (1,25-OH D) synthesis to maintain serum calcium. Low serum calcium stimulates PTH; high calcium suppresses it via negative feedback.

Anatomic location is variable — embryologic migration leaves 10-15% of patients with ectopic (intrathyroidal, mediastinal, retro-oesophageal, carotid sheath) glands. This is important surgically — a cause of failed first exploration.

Types of hyperparathyroidism: Primary hyperparathyroidism (most common) — autonomous PTH production from the gland itself. 85% single adenoma, 10-15% four-gland hyperplasia (common in MEN syndromes and familial forms), 1-2% carcinoma (rare; severe hypercalcaemia and palpable hard mass).

Secondary hyperparathyroidism — reactive PTH elevation from chronic hypocalcaemia (chronic kidney failure, vitamin D deficiency); serum calcium is low or normal.

Tertiary hyperparathyroidism — long-standing secondary disease becomes autonomous (typically after prolonged renal failure and dialysis).

Incidence: 1-2 per 1000 adults; 2-3-fold higher in postmenopausal women. Rises with age. With widespread screening, 75-80% of cases are now asymptomatic at diagnosis. We expand on the clinical framework in our thyroid surgery programme.

Classic mnemonic — stones (kidney stones, nephrocalcinosis), bones (osteoporosis, osteitis fibrosa cystica), abdominal (peptic ulcer, pancreatitis, constipation, dyspepsia), psychic (depression, anxiety, cognitive impairment, fatigue). In modern practice 75-80% of cases are diagnosed asymptomatically at screening.

Renal: nephrolithiasis (calcium oxalate or phosphate stones), nephrocalcinosis (parenchymal calcium deposition), chronic kidney failure, polyuria, polydipsia. Hypercalcaemia disrupts tubular ADH response, causing thirst.

Skeletal: osteoporosis (especially cortical bone — distal radius, femoral neck — affected before trabecular spine; pattern specific to PTH). Osteitis fibrosa cystica (advanced — intraosseous cysts, brown tumour); now rare. Pathologic fracture risk increased.

GI: dyspepsia, constipation, peptic ulcer (stimulates gastrin secretion), pancreatitis (calcium trypsin activation).

Neuropsychiatric: fatigue, depression, anxiety, difficulty concentrating, memory problems ("brain fog"). Patients often attribute these to "age" or "stress" and they are missed. Marked improvement after surgery is common.

Cardiovascular: hypertension (50% of cases), left ventricular hypertrophy, vascular and valve calcification, arrhythmia (short QT). Some studies show increased cardiovascular mortality.

Other: pruritus, calcium deposits (band keratopathy, calcific tendinitis), gout/pseudogout flares, may trigger hypertensive crisis.

Screening: serum calcium (ideally ionised or albumin-corrected). Normal range 8.5-10.5 mg/dL (2.1-2.6 mmol/L); above 10.5 is hypercalcaemic.

Combined diagnostic criteria: elevated calcium + elevated or inappropriately normal PTH + 24-hour urinary calcium (to exclude familial hypocalciuric hypercalcaemia — in which urinary calcium is low).

PTH level: in the presence of hypercalcaemia, PTH should be suppressed (negative feedback). Normal or elevated PTH points to autonomous PTH secretion (parathyroid disease). Intact PTH is preferred in atypical cases.

Vitamin D status: low 25-OH D can mask hyperparathyroidism and increase post-operative hungry bone syndrome risk. Vitamin D deficiency should be corrected first.

Renal evaluation: serum creatinine, urinalysis, urinary calcium, 24-hour urine calcium (>400 mg/day hypercalciuria), renal US for nephrolithiasis.

Bone evaluation: DEXA (bone mineral density — including distal radius). Osteoporosis/osteopenia strengthens surgical indication.

Imaging — after primary diagnosis, for pre-operative localisation: Tc-99m sestamibi scintigraphy (optimally fused with SPECT/CT — sensitivity 75-85%, specificity >95%, identifies ectopic adenoma). Neck ultrasound (combined with scintigraphy >90% accuracy); 4D-CT and MRI in selected cases (reoperation, failed first exploration, small adenoma, multi-gland suspicion). PET (11C-choline or 18F-choline) as an advanced option.

Familial syndrome screening: especially in <40 years, multi-gland disease, persistent disease — MEN1 (genetic test), MEN2A (RET mutation), familial hyperparathyroidism-jaw tumour syndrome (CDC73 mutation), familial hypocalciuric hypercalcaemia (CASR mutation). Step-by-step details: thyroidectomy page.

Surgical indications (NIH consensus 2014, updated 2022): all symptomatic patients. For asymptomatic: age <50, calcium >1 mg/dL above upper normal, creatinine clearance <60 mL/min, T-score in osteoporotic range (≤-2.5), vertebral fracture, 24h urine calcium >400 mg, nephrolithiasis or nephrocalcinosis. Surgery offered if one or more met.

Minimally invasive parathyroidectomy (MIP): targeted approach to a single adenoma through small (2-3 cm) cervical incision. Prerequisite: preoperative localisation. Concordant sestamibi + ultrasound yields >95% single-session success.

Operative course: general anaesthesia (or local + sedation), small transverse neck incision, direct approach to the localised gland, careful resection sparing surrounding tissue. Operation 30-60 minutes.

Intraoperative PTH (ioPTH) measurement: evidence-based standard. PTH measured pre-resection (baseline) and 10 minutes post-resection; >50% drop into normal range confirms cure (Miami criterion). If it does not drop, other glands are explored (bilateral exploration).

Bilateral 4-gland exploration: required for 4-gland hyperplasia (MEN syndromes, familial), failed localisation, persistent ioPTH elevation. 3.5-gland resection is standard (the half remaining gland or one autotransplanted to the forearm subcutaneously, to avoid post-op hypoparathyroidism).

Outcomes: in experienced surgical centres success >95%. Persistent hypercalcaemia (within first 6 months postop) 2-5%; recurrent (after 6 months) 1-3%. Complications: recurrent laryngeal nerve palsy (1-2% — transient, ~0.5% permanent), hypoparathyroidism (transient 10-20%, permanent <2%), bleeding, infection.

Reoperation: persistent disease after failed first surgery. More difficult, higher complication risk; should be in a high-volume endocrine surgical centre. Detailed re-localisation (4D-CT, PET) is mandatory before.

First 24 hours postoperatively: serum calcium is monitored. Normalised patients are discharged.

Hypocalcaemia management: some patients develop transient hypocalcaemia (especially with severe bone disease, "hungry bone syndrome" — bones avidly take up calcium). Oral calcium (1500-3000 mg/day) and active vitamin D (calcitriol 0.5-1 mcg/day) replacement. IV calcium gluconate in severe cases. Usually resolves in 1-2 weeks.

Long-term follow-up: postop at 6, 12 months and then yearly serum calcium, PTH, creatinine, urinary calcium. DEXA repeated within 1-2 years (to confirm bone mineral density improvement).

Bone density: significant BMD gain in the first 2 years postop (lumbar spine 5-10%, total femur 3-5%). Reversal of osteoporosis improves quality of life and reduces fracture risk.

Renal outcome: nephrolithiasis recurrence drops dramatically. Existing stones treated (ESWL, ureteroscopy). Renal function (GFR) may improve mildly; established advanced renal failure does not reverse.

Neuropsychiatric: fatigue, depression and cognitive dysfunction usually improve markedly within 3-6 months. Studies show quality of life improvement even in formally "asymptomatic" patients.

Lifestyle for asymptomatic patients (if surgery deferred): ample fluids (3 L/day), 4-6 servings of fresh fruit and vegetables daily, adequate vitamin D (1000-2000 IU/day), regular exercise, smoking cessation, alcohol moderation.

In surgery-refused or contraindicated patients: 6-monthly serum calcium and PTH, annual DEXA, renal imaging. Calcimimetic (cinacalcet) to lower PTH and calcium; bisphosphonate (alendronate, zoledronate) or denosumab for bone protection. This does not cure — it controls symptoms. Related reading: our Istanbul thyroid surgery page.